Content Conference Coverage Conferences IDWeek 2014
IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes
- Details
- Category: HIV Treatment
- Created on Wednesday, 15 October 2014 00:00
While making medications free can remove barriers to access for individuals who cannot pay for treatment, data suggest that for most people accessing care in industrialized countries, "making medications available for free or low cost will not solve problems with medication non-adherence," according to a presentation by Kevin Volpp from the University of Pennsylvania last week at IDWeek 2014 in Philadelphia.
IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower HIV Rebound After Stopping ART
- Details
- Category: Approved HIV Drugs
- Created on Wednesday, 22 October 2014 00:00
HIV viral load usually begins to rise again within 4 to 8 weeks after stopping antiretroviral therapy (ART), though starting treatment earlier in the course of infection and using a non-nucleoside reverse transcriptase inhibitor (NNRTI) may delay viral rebound, according to study findings presented at IDWeek 2014 last week in Philadelphia.
IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems
- Details
- Category: Approved HIV Drugs
- Created on Friday, 17 October 2014 00:00
Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.
IDWeek 2014: NNRTIs and Protease Inhibitors Both Good for First ART, Channeling Affects Choices
- Details
- Category: Approved HIV Drugs
- Created on Friday, 17 October 2014 00:00
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 last week in Philadelphia. A related study shed light on factors affecting choice of initial antiretroviral regimen.
IDWeek 2014: Efavirenz Not Linked to Suicide in Analysis of Insurance Records
- Details
- Category: Approved HIV Drugs
- Created on Wednesday, 15 October 2014 00:00
The non-nucleoside reverse transcriptase inhibitor efavirenz (Sustiva, also in the Atripla single-tablet regimen) was not associated with a higher rate of suicidal thoughts or attempts in an analysis conducted by manufacturer Bristol-Myers Squibb (BMS), researchers reported at the 2014 IDWeek meeting last week in Philadelphia.
More Articles...
- IDWeek 2014: Complera Matches Atripla for Women Starting HIV Treatment
- IDWeek 2014: HIV Attachment Inhibitor BMS-663068 Works Well Across Patient Subgroups
- IDWeek 2014: HIV Care Cascade at Kaiser Permanente Varies by Sex and Age
- IDWeek 2014: Social Network Strategies Encourage HIV Testing
- IDWeek 2014: Acute Retroviral Syndrome Linked to Higher HIV Levels in Blood, Gut and Brain
- IDWeek 2014: Hepatitis B Relapse Is Common After Stopping Antiviral Therapy
- IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials
- IDWeek 2014: Sofosbuvir/Ledipasvir Safe and Effective for Genotype 1 HCV
- IDWeek 2014: Age, Sex, and Race Predict Spontaneous Hepatitis C Virus Clearance
- IDWeek 2014: HIV and Hepatitis B Coinfection Linked to Hip Fractures
- IDWeek 2014: Study Shows HIV/HCV Coinfected Women Have Lower Bone Density
- IDWeek 2014: HIV/HCV Coinfected People Do Not Have Poorer CD4 Cell Recovery
- IDWeek 2014: Syphilis Cases Increase Among Men with HIV Despite Risk Reduction Counseling
Web Design and Development by